Contrasting BioMarin Pharmaceutical (BMRN) & Sinovac Biotech (SVA)
BioMarin Pharmaceutical (NASDAQ: BMRN) and Sinovac Biotech (NASDAQ:SVA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
This is a breakdown of current ratings and recommmendations for BioMarin Pharmaceutical and Sinovac Biotech, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioMarin Pharmaceutical presently has a consensus price target of $113.52, suggesting a potential upside of 37.26%. Given BioMarin Pharmaceutical’s higher possible upside, equities analysts plainly believe BioMarin Pharmaceutical is more favorable than Sinovac Biotech.
Valuation & Earnings
This table compares BioMarin Pharmaceutical and Sinovac Biotech’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|BioMarin Pharmaceutical||$1.12 billion||13.01||-$630.21 million||($0.83)||-99.65|
|Sinovac Biotech||$72.43 million||6.27||-$1.07 million||($0.08)||-99.61|
Sinovac Biotech has higher revenue, but lower earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Sinovac Biotech, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
96.0% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 31.5% of Sinovac Biotech shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
BioMarin Pharmaceutical has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Sinovac Biotech has a beta of 0.1, indicating that its share price is 90% less volatile than the S&P 500.
This table compares BioMarin Pharmaceutical and Sinovac Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
BioMarin Pharmaceutical beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
Sinovac Biotech Company Profile
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.